Roche plans to initiate a Phase 2 trial combining petrelintide and enicepatide later this year, according to ADA26 reporting. The companies are positioning the dual-incretin approach as a path to both improved safety and stronger efficacy, with the combination strategy aimed at differentiating against existing once-weekly obesity regimens.